Louisiana case could curb abortion pill access nationwide

Louisiana is pressing a federal court to make the Food and Drug Administration restore a nationwide in-person dispensing rule for mifepristone, a change that would reach far beyond the state’s own abortion ban. If the state gets its way, telehealth prescribing and mail delivery would be cut back across the country, reshaping access to the abortion pill and the miscarriage care that depends on it.

The case, Louisiana v. FDA, was filed in October 2025 by the State of Louisiana and seeks to roll back FDA changes that made the drug easier to obtain. The FDA first approved mifepristone in 2000, then loosened its Risk Evaluation and Mitigation Strategy on January 3, 2023, allowing telehealth prescribing and mail distribution. That expansion matters because medication abortion now accounts for 63% of abortions in the United States, according to the Guttmacher Institute, and advocacy groups say about 7.5 million Americans have used mifepristone safely since approval.

The stakes are especially sharp in Louisiana, where abortion is banned. State officials have argued that pills are still reaching patients from outside the state, with one report saying nearly 1,000 abortions a month are being administered in Louisiana through medication obtained elsewhere. That is why the lawsuit is not just about one drug or one state. It is about whether anti-abortion litigation can effectively impose a national restriction through the federal courts and the FDA.

The fight accelerated in the spring. On April 7, a federal judge in Louisiana paused the case while the Trump administration reviewed the drug’s safety. On May 1, the U.S. Court of Appeals for the Fifth Circuit went further and ordered nationwide restrictions, blocking the FDA’s telehealth and mail-distribution policy. Then, on May 14, the U.S. Supreme Court preserved access to mifepristone by putting the lower-court order on hold while the lawsuit continues. The result is a legal standoff that has kept the drug available for now, but only after a series of fast-moving rulings that could still reshape access.

The politics are no less volatile than the law. Anti-abortion activists have grown frustrated with Donald Trump for not moving aggressively enough on abortion restrictions, and Reuters reported that they met with White House officials on May 8 amid that tension. For Republicans, the risk is clear: a fight over mifepristone could trigger the kind of broad abortion backlash that has repeatedly complicated the party’s electoral math, even as the administration tries to keep the issue at arm’s length.